Upload
Featured Recent Articles Topics Login Upload

Search Results for 'Biosimilars-Patient'

Biosimilars-Patient published presentations and documents on DocSlides.

  What is the value of Real-World Evidence for Biosimilars?
  What is the value of Real-World Evidence for Biosimilars?
by bitsy
Disclaimer. This panel is moderated by Dr. Delphin...
Synergy Satellite Event - Biosimilars in colorectal cancer
Synergy Satellite Event - Biosimilars in colorectal cancer
by mia
– what's your gut feeling?. 25th Anniversary EAH...
Biosimilars in emerging markets- regulatory and Commercial considerations
Biosimilars in emerging markets- regulatory and Commercial considerations
by jane-oiler
OMIC Group. Biosimilars 2104. Hyderabad. India. 2...
Biosimilars are effective and safe and should immediately replace innovator molecules in the NHS
Biosimilars are effective and safe and should immediately replace innovator molecules in the NHS
by myesha-ticknor
Dr Chris Deighton. Consultant Rheumatologist . Co...
Biosimilars & EU regulation
Biosimilars & EU regulation
by karlyn-bohler
Alice DOMINIQUE - M2 AREIPS. 1. Content. 2. Defin...
Applying Biosimilars in Hematologic Cancers
Applying Biosimilars in Hematologic Cancers
by conchita-marotz
This program will include a discussion of off-lab...
Biosimilars in the Real World
Biosimilars in the Real World
by liane-varnes
Introduction/Overview . PLANETRA Extension Study:...
US Regulatory Pathway For Biosimilars
US Regulatory Pathway For Biosimilars
by cheryl-pisano
Practical Legal/Regulatory Considerations Arising...
Biosimilars in RA: A Blessing or a Curse?
Biosimilars in RA: A Blessing or a Curse?
by conchita-marotz
Introduction/Overview . What Is a Biosimilar?. Di...
Biosimilars
Biosimilars
by lindy-dunigan
Knowledge Connect Slide Resource. This slide dec...
Category 1: Defining Terms
Category 1: Defining Terms
by jasmine
Clue: . A biologic product with no clinically mean...
1 Immunogenicity The key safety issue for biosimilars
1 Immunogenicity The key safety issue for biosimilars
by gelbero
Prof. Ibrahim A. . Alsarra. Professor . of . Phar...
Budget impact and cost-effectiveness of oncology
Budget impact and cost-effectiveness of oncology
by roxanne
biosimilars. Prof. dr. Steven Simoens. Health econ...
CHALLENGES FACED IN THE DEVELOPMENT OF BIOSIMILARS
CHALLENGES FACED IN THE DEVELOPMENT OF BIOSIMILARS
by iamamercy
Dr.G.Hima. . Bindu. ...
Bio similars A Presentation
Bio similars A Presentation
by kittie-lecroy
By. ANSHUL . SHARMA. Graduate Research Scholar. D...
About OMICS Group OMICS Group International is an amalgamation of 
About OMICS Group OMICS Group International is an amalgamation of 
by sherrill-nordquist
Open Access publications.  and worldwide interna...
Biological Products: concepts, naming,
Biological Products: concepts, naming,
by faustina-dinatale
interchangeability,extrapolation. and safety. Dr...
Understanding Biologics Biologics and Biosimilars
Understanding Biologics Biologics and Biosimilars
by calandra-battersby
Animation: What Are Biologics?. Production of Bio...
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
by calandra-battersby
OMICS Group Biosimilars 2015 Birmingham, UK. 10-1...
Acceptable changes in quality attributes of glycosylated bi
Acceptable changes in quality attributes of glycosylated bi
by debby-jeon
Schiestl M, Stangler T, Torella C, et al. . Nat B...
Biosimilars in the united states – Update on FDA Impleme
Biosimilars in the united states – Update on FDA Impleme
by test
James C. Shehan. Hyman, Phelps & McNamara, P....
Distinguishable INNs: A Global Solution
Distinguishable INNs: A Global Solution
by trish-goza
Richard . Dolinar. , MD. Chairman, Alliance for S...
A QUM partnership approach to regulating
A QUM partnership approach to regulating
by liane-varnes
biosimilars. in Australia. David Lim, Evan Siege...
Biosimilars and biologics –
Biosimilars and biologics –
by gelbero
What does personalisation . mean . for you?. Ian N...
JMP for Biosimilars : Tools for Analytical Similarity
JMP for Biosimilars : Tools for Analytical Similarity
by erica
Sept 16, 2015. W. Heath Rushing, . Adsurgo. LLC. ...
INSIGHTS INTO THE MARKET
INSIGHTS INTO THE MARKET
by summer
FOR INFLIXIMABTable of ContentsThe Evolving Landsc...
TEVA PHARMACEUTICALS
TEVA PHARMACEUTICALS
by adah
Athlani. Audrey ; . Durlin. Stéphanie ; Jauregu...
Phil Johnson MS RPh Safe School Meds, Principle Partner
Phil Johnson MS RPh Safe School Meds, Principle Partner
by yoshiko-marsland
Moffitt Cancer Center, Director of Pharmacy (Reti...
Comparison of US/EU Biosimilar
Comparison of US/EU Biosimilar
by aaron
Guidelines. Kamali Chance, MPH, PhD, RAC. Senior...
U.S. Biosimilars: An Introduction
U.S. Biosimilars: An Introduction
by calandra-battersby
Disclaimers. :. By 2016, 7 of the top 10 pharmace...
Comparison of US/EU Biosimilar
Comparison of US/EU Biosimilar
by myesha-ticknor
Guidelines. Kamali Chance, MPH, PhD, RAC. Senior...
Biosimilars Guideline – a Summary of the Industry Comments
Biosimilars Guideline – a Summary of the Industry Comments
by marina-yarberry
M Bredenhann | Nycomed | 19.11.10. BIOSIMILAR...
Biosimilars: Regulation and Litigation
Biosimilars: Regulation and Litigation
by mitsue-stanley
Agenda. Key Regulatory Exclusivities for Biologic...
Comparison of US/EU Biosimilar
Comparison of US/EU Biosimilar
by danika-pritchard
Guidelines. Kamali Chance, MPH, PhD, RAC. Senior...
Faculty Leonard H. Calabrese, DO
Faculty Leonard H. Calabrese, DO
by trish-goza
Professor of Medicine. Cleveland Clinic Lerner Co...
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
by stefany-barnette
OMIC Group Biosimilars 2014. Hyderabad India. 27-...
Biosimilars 2012 AIPLA Webinar
Biosimilars 2012 AIPLA Webinar
by stefany-barnette
September 25, 2012. 1. Denise. Kettelberger, PhD...
Phil Johnson MS
Phil Johnson MS
by stefany-barnette
RPh. Safe School Meds, Principle Partner. Moffitt...
Interchangeable Biosimilars: The Future of Affordable MedicineFDA is i
Interchangeable Biosimilars: The Future of Affordable MedicineFDA is i
by celsa-spraggs
Interchangeability = SubstitutabilityInterchangeab...
Biosimilars: Additional Questions and Answers Regarding Implementatio
Biosimilars: Additional Questions and Answers Regarding Implementatio
by liane-varnes
&#x/Att;¬he; [/; ott;&#xom ];&#x/BBo...